Serengen GmbH

Before founding Serengen, we worked as medicinal chemists for more than 20 years, where we have taken many compounds from screening to lead optimisation to candidate selection. Serengen and Deargen have partnered up to integrate their DEL and AI platforms for a faster, more affordable and effective drug discovery. As Louis Pasteur said: „Chance favours only the prepared mind.” At Serengen, we are prepared! Our proprietary technology offers the fastest and most cost-efficient approach to hit identification that allows for serendipity and delivers high quality hits. Benefit from serendipity in hit ID with a breakthrough DEL technology that offers lower hit attrition and lower follow-up costs.